Tasca Therapeutics focuses on advancing drug discovery by targeting post-translational modifications and leveraging metabolic synergy to enhance the druggable proteome. This approach aims to identify and develop small molecule therapeutics that can effectively interact with proteins altered by post-translational modifications, which are critical in various disease processes, particularly in oncology. By expanding the understanding of these modifications, Tasca Therapeutics seeks to unlock new therapeutic avenues and improve treatment outcomes for cancer patients.

The company is actively developing a pipeline of small molecule therapeutics aimed at addressing multiple oncology indications. This pipeline reflects Tasca Therapeutics' commitment to innovating cancer treatment by creating targeted therapies that can potentially overcome the limitations of existing treatments. By focusing on the intricate relationship between metabolic pathways and protein modifications, Tasca Therapeutics aims to create more effective and precise therapeutic options for patients battling cancer.

United States

Targeting post-translational modification and metabolic synergy to expand and effectively target the druggable proteome

Tasca Therapeutics

Company Details